Semler Announces Clinical Study Published Using QuantaFlo® as an Aid for Diagnosis of Heart Dysfunction in the Primary Care Setting
The article, "Clinical Evaluation of Volume Plethysmography as an Aid for Diagnosis of Heart Failure in the Primary Care Setting,"1 which was co-authored by individuals affiliated with
"Health care providers now have a point-of-care, low-cost, accurate means for detecting potential heart dysfunction in the primary care setting before overt signs or symptoms present," said
Semler's QuantaFlo for HD is a portable, easy-to-operate non-invasive test, which takes less than five minutes to perform and can be administered by a healthcare professional in a clinic or home setting, providing immediate results. It may be sold as an SAAS upgrade for current QuantaFlo for PAD customers, or may be sold separately.
Echo and Heart Failure in
- An estimated 6.2 million persons over age 20 have been diagnosed with heart failure.
- About one million new cases are diagnosed annually.
- Heart failure is a primary diagnosis in over one million hospitalizations annually.
- The total cost of heart failure care exceeds
- Mortality rates after hospitalization for heart failure are 31% within one year after diagnosis.
Heart disease may be "silent" and remain undiagnosed until a person experiences signs or symptoms of a myocardial infarction, heart failure or an arrhythmia. Multiple studies have shown that asymptomatic heart failure is much more common than symptomatic heart failure, but often unsuspected by the HCP. The most common way to diagnose heart failure is with Echo, requiring a referral to a cardiologist and a cardiovascular technician. In contrast, QuantaFlo HD may offer the ability to perform an inexpensive, early screening program for all patients at risk of heart failure, and to refer for Echo, as needed. The goal is to enable HCPs to more effectively encourage patients to adopt healthier lifestyles and to optimize proven guideline-directed medical therapies earlier, with the potential of improving long-term health outcomes.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers.
This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "goal," "may," "will," "intend," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding the use of QuantaFlo as an aid for diagnosis of heart dysfunction, the benefits of early detection, early screening with QuantaFlo and impact on HCP and patient care, among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause forward looking statements to differ materially from those discussed here, such as whether or not QuantaFlo can successfully aid in the diagnosis of heart dysfunction and whether or not
Susan A. Noonan
S.A. Noonan Communications
917 513 5303
1 Howell SC, Master RC (2023) Clinical Evaluation of Volume Plethysmography as an Aid for Diagnosis of Heart Failure in the Primary Care Setting. J Prev Med Vol.8 No.2: 184.
View original content to download multimedia:https://www.prnewswire.com/news-releases/semler-announces-clinical-study-published-using-quantaflo-as-an-aid-for-diagnosis-of-heart-dysfunction-in-the-primary-care-setting-301760065.html